The purpose of this study is to identify the safety, tolerability and maximum-tolerated-dose of the oral formulation of SLC-0111 in combination with IV gemcitabine in those with metastatic pancreatic ductal cancer.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.